{"filing":{"accession_number":"0001628280-26-055490","cik":"0001662579","ticker":"CCCC","company_name":"C4 Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"cccc-20260811.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1662579/000162828026055490/cccc-20260811.htm"},"events":[{"id":26862,"run_id":24430,"accession_number":"0001628280-26-055490","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"C4 Therapeutics issued a press release on August 11, 2026, announcing its financial results for the quarter ended June 30, 2026, including revenue ($6.6M), R\u0026D expense ($24.5M), G\u0026A expense ($8.6M), net loss ($23.6M), and cash position ($300.4M). The filing includes condensed consolidated balance sheet and statements of operations data, which are hallmarks of a quarterly earnings release under Item 2.02.","company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28140,"accession_number":"0001628280-26-055490","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"C4 Therapeutics issued a press release on August 11, 2026, announcing its financial results for the quarter ended June 30, 2026, including revenue ($6.6M), R\u0026D expense ($24.5M), G\u0026A expense ($8.6M), net loss ($23.6M), and cash position ($300.4M). The filing includes condensed consolidated balance sheet and statements of operations data, which are hallmarks of a quarterly earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:15:43.807641+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28140,"accession_number":"0001628280-26-055490","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"C4 Therapeutics issued a press release on August 11, 2026, announcing its financial results for the quarter ended June 30, 2026, including revenue ($6.6M), R\u0026D expense ($24.5M), G\u0026A expense ($8.6M), net loss ($23.6M), and cash position ($300.4M). The filing includes condensed consolidated balance sheet and statements of operations data, which are hallmarks of a quarterly earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:15:43.807641+00:00","company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","filing_date":"2026-08-11"}]}